Joseph Stringer
Stock Analyst at Needham
(3.98)
# 595
Out of 4,944 analysts
308
Total ratings
45.22%
Success rate
12.26%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Stringer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Maintains: Buy | $54 → $74 | $63.25 | +17.00% | 14 | Aug 8, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $377 → $478 | $432.52 | +10.52% | 23 | Jul 31, 2025 | |
| GILD Gilead Sciences | Upgrades: Buy | $133 | $120.14 | +10.70% | 7 | Jul 25, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $72 → $95 | $97.86 | -2.92% | 25 | Jul 9, 2025 | |
| STOK Stoke Therapeutics | Reiterates: Buy | $22 | $16.91 | +30.10% | 23 | Jul 1, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $28 | $10.48 | +167.18% | 52 | Jun 6, 2025 | |
| VIR Vir Biotechnology | Reiterates: Buy | $14 | $4.57 | +206.35% | 18 | May 22, 2025 | |
| ANNX Annexon | Maintains: Buy | $16 → $11 | $2.60 | +323.08% | 19 | May 13, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $40 → $29 | $26.58 | +9.10% | 20 | May 7, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Hold | n/a | $395.92 | - | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $55 | $43.10 | +27.61% | 21 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $60 | $46.15 | +30.01% | 17 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $90 | $31.55 | +185.26% | 17 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $1.11 | - | 13 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $10 | $1.60 | +525.00% | 17 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $26.89 | - | 8 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $37 | $25.13 | +47.23% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $18 | $12.42 | +44.93% | 2 | Aug 24, 2021 |
Cidara Therapeutics
Aug 8, 2025
Maintains: Buy
Price Target: $54 → $74
Current: $63.25
Upside: +17.00%
Alnylam Pharmaceuticals
Jul 31, 2025
Maintains: Buy
Price Target: $377 → $478
Current: $432.52
Upside: +10.52%
Gilead Sciences
Jul 25, 2025
Upgrades: Buy
Price Target: $133
Current: $120.14
Upside: +10.70%
Rhythm Pharmaceuticals
Jul 9, 2025
Maintains: Buy
Price Target: $72 → $95
Current: $97.86
Upside: -2.92%
Stoke Therapeutics
Jul 1, 2025
Reiterates: Buy
Price Target: $22
Current: $16.91
Upside: +30.10%
Phathom Pharmaceuticals
Jun 6, 2025
Maintains: Buy
Price Target: $28
Current: $10.48
Upside: +167.18%
Vir Biotechnology
May 22, 2025
Reiterates: Buy
Price Target: $14
Current: $4.57
Upside: +206.35%
Annexon
May 13, 2025
Maintains: Buy
Price Target: $16 → $11
Current: $2.60
Upside: +323.08%
Apellis Pharmaceuticals
May 7, 2025
Maintains: Buy
Price Target: $40 → $29
Current: $26.58
Upside: +9.10%
Vertex Pharmaceuticals
May 6, 2025
Reiterates: Hold
Price Target: n/a
Current: $395.92
Upside: -
Apr 30, 2025
Maintains: Buy
Price Target: $60 → $55
Current: $43.10
Upside: +27.61%
Apr 9, 2025
Reiterates: Buy
Price Target: $60
Current: $46.15
Upside: +30.01%
Apr 8, 2025
Reiterates: Buy
Price Target: $90
Current: $31.55
Upside: +185.26%
Mar 7, 2025
Reiterates: Hold
Price Target: n/a
Current: $1.11
Upside: -
Mar 4, 2025
Downgrades: Hold
Price Target: $10
Current: $1.60
Upside: +525.00%
Nov 8, 2024
Reiterates: Hold
Price Target: n/a
Current: $26.89
Upside: -
Jan 24, 2024
Upgrades: Buy
Price Target: $37
Current: $25.13
Upside: +47.23%
Aug 24, 2021
Maintains: Buy
Price Target: $32 → $18
Current: $12.42
Upside: +44.93%